Evercore ISI lowered the firm’s price target on AN2 Therapeutics to $2 from $7 and keeps an In Line rating on the shares. The firm remains on the sidelines until it gains more visibility with upcoming Phase 2 data, though it has updated its model and delayed expectations for a launch of epetraborole to 2028 from 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANTX:
- AN2 Therapeutics reports Q1 EPS (56c), consensus (62c)
- AN2 Therapeutics upgraded to Outperform from Market Perform at JMP Securities
- AN2 Therapeutics’ High-Stakes Gamble: Navigating FDA Approval for Epetraborole Amid Clinical Trial Uncertainties
- AN2 Therapeutics reports Q4 EPS (57c), consensus (75c)
- ANTX Earnings this Week: How Will it Perform?
Questions or Comments about the article? Write to editor@tipranks.com